01:49 PM EDT, 04/15/2024 (MT Newswires) -- Eagle Pharmaceuticals ( EGRX ) shares climbed 9% in recent trading after the company said Monday that it will present phase III trial data showing that intravenous amisulpride may sustain an antiemetic effect in adult surgical patients with moderate to high risk of postoperative nausea and vomiting.

The data relate to a subset of patients who failed antiemetic prophylaxis, the company said, adding that these show that a single 10 mg dose "is capable of delivering a sustained response" for PONV rescue, the company said.

Additional data will be presented Tuesday at a conference in Florida, the company said